Correction: Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: A systematic review and network meta-analysis (BMJ Open (2015) 5 (e009183) DOI: 10.1136/bmjopen-2015-009183);Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: A systematic review and network meta-analysis

BMJ Open

Volumn 5, Issue 10, 2015, Pages

  Tricco, Andrea C ^a,b   Strifler, Lisa ^a   Veroniki, Areti Angeliki ^a   Yazdi, Fatemeh ^c   Khan, Paul A ^a   Scott, Alistair ^a   Ng, Carmen ^a   Antony, Jesmin ^a   Mrklas, Kelly ^a,d   D'Souza, Jennifer ^a   Cardoso, Roberta ^a   Straus, Sharon E ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d ALBERTA HEALTH SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; TRIAMCINOLONE ACETONIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; CLASSIFICATION; DISEASE COURSE; INHALATIONAL DRUG ADMINISTRATION; MORTALITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; DISEASE PROGRESSION; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84949228062     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009183corr1     Document Type: Erratum

References (53)

1. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;5:CD007891.
2. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;(3):CD008532.
3. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;(4):CD006829.
4. Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;8:CD006826.
5. Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;11:CD003794.
6. Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res 2013;14:100.
7. Karabis A, Lindner L, Mocarski M, et al. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis 2013;8:405-23.
8. Puhan MA, Bachmann LM, Kleijnen J, et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009;7:2.
9. Mills EJ, Druyts E, Ghement I, et al. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol 2011;3:107-29.
10. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
11. Ontario Drug Policy Research Network. Drug Class Review: inhaled corticosteroids (ICS) + long-acting beta-agonists (LABA) combination products for treatment of chronic obstructive pulmonary disease (COPD). http://www.odprn.ca/wp-content/uploads/2014/01/ ODPRN-SR-protocol-final-2.pdf (accessed Jan 2015).
12. Khan S, Mascarenhas A, Dufresne K, et al. ODPRN. Final report: inhaled corticosteroids and long acting beta agonists (ICS/LABA) for the treatment of chronic obstructive pulmonary disease (COPD). http://www.odprn.ca/wp-content/uploads/2015/01/ICS-LABA-COPDQualitative-Report-Final-16-01-15.pdf (accessed Jan 2015).
13. Morrison A, Polisena J, Husereau D, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 2012;28:138-44.
14. Hopewell S, Clarke MJ, Stewart L, et al. Time to publication for results of clinical trials. The Cochrane Library. 2007.
15. Sampson M, McGowan J, Cogo E, et al. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol 2009;62:944-52.
16. Kew KM, Li T. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: an overview and network meta-analysis. Cochrane Database Syst Rev 2013;(10): CD010178.
17. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
18. Raudenbush SW. Analyzing effect sizes: random effects models. In: Cooper LVH, Valentine JC, eds. The handbook of research synthesis and meta-analysis. 2nd edn. New York: Russell Sage Foundation, 2009:295-315.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
20. Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110.
21. Veroniki AA, Vasiliadis HS, Higgins JP, et al. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013;42:332-45.
22. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.
23. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91.
24. Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549.
25. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009;172:137-59.
26. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS ONE 2013;8:e76654.
27. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
28. R Core Team. R: A language and environment for statistical computing. http://www.R-project.org (accessed Jan 2015).
29. Schwarzer G. meta: Meta-Analysis with R. R package version 4.0-3. http://CRAN.R-project.org/package=meta (accessed Jan 2015).
30. White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J 2011;11:255-70.
31. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP, 2013.
32. Thomas N. Overview: OpenBUGS website. http://www.openbugs. net/w/Overview (accessed Jan 2015).
33. Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 2012;41:818-27.
34. Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med 2014;24:14003.
35. Tieu J, Bain E, Middleton P, et al. Interconception care for women with a history of gestational diabetes for improving maternal and infant outcomes. Cochrane Database Syst Rev 2013;6:CD010211.
36. Andrade-Castellanos Carlos A, Colunga-Lozano Luis E, Delgado-Figueroa N, et al. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev 2014;9:CD011281.
37. Shen W, Li Y, Zhang Y, et al. Acupuncture for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2013;4:CD010491.
38. Sekiya M, Kawayama T, Fukuchi Y, et al. Safety and efficacy of NVA237 once daily in Japanese patients: the GLOW4 trial. Eur Respir J 2012;40(Suppl 56):P2103.
39. Brown J, Crawford Tineke J, Alsweiler J, et al. Myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev 2015;4:CD011507.
40. Crawford Tineke J, Brown J, Alsweiler J, et al. Different intensities of glycaemic control for women with gestational diabetes mellitus. Cochrane Database Syst Rev 2015;4:CD011624.
41. Flowers N, Hartley L, Todkill D, et al. Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2014;12:CD010405.
42. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014;2:472-86.
43. Wadbo M, Lofdahl CG, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002;20:1138-46.
44. Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012;142:119-27.
45. Wielders PL, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J 2013;42:972-81.
46. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/ vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respir Med 2013;107:550-9.
47. Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68:48-56.
48. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev 2014;3:CD010844.
49. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:CD010115.
50. Insulander P, Juhlin-Dannfelt A, Freyschuss U, et al. Electrophysiologic effects of salbutamol, a beta2-selective agonist. J Cardiovasc Electrophysiol 2004;15:316-22.
51. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-21.
52. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005;65:1595-610.
53. Nikolakopoulou A, Chaimani A, Veroniki AA, et al. Characteristics of networks of interventions: a description of a database of 186 published networks. PLoS ONE 2014;9:e86754.